Prevention of Bone Loss in the Postmenopausal Woman with Strontium Ranelate
Commencing from the age of 35 years，bone loss is accelerated after the menopause due toleek of secretion of estrogens. This hone loss is secondary to an increase in bone turnoverwith bone resorption being more increased than bone formation. Within the space of a few years，postmenopausal women may be affected by osteopenia and progressively by osteopomsis and their clinical consequences. Strontium ranelate is answ drug with a unique made of action，both increasing bone formation and decreasing bone resotpaon，which rebalancesbone turnover in favor of formation.
Prevention Bone Loss the Postmenopausal Strontium Ranelate
Harry Genant
University of Californaia,San Francisco & synarc,Inc,San Francisco,CA
国内会议
北京
英文
20-22
2007-10-19（万方平台首次上网日期，不代表论文的发表时间）